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Immunorestitution Disease Involving the Innate and Adaptive Response
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Immunorestitution disease (IRD) is defined as an acute symptomatic or paradoxical de-
terioration of a (presumably) preexisting infection that is temporally related to the recovery
of the immune system. We report the temporal sequence of events that led to IRD caused by
Pneumocystis carinii and Aspergillus terreus in 2 human immunodeficiency virus (HIV)–
negative patients soon after the recovery of adaptive and innate immunity, respectively, and
we review episodes noted in the English-language literature that fit the definition of IRD (109
episodes in 107 patients). The median time from the recovery of neutrophil counts or ter-
mination of steroid therapy to the development of IRD was 8 days in cases of pulmonary
aspergillosis (23 episodes) and hepatosplenic candidiasis (8) and 21 days for viral diseases
such as hepatitis B (24) and viral pneumonitis (6). For IRD due to mycobacteriosis (27
episodes) and cryptococcosis (4) in HIV-positive patients, the median interval between the
initiation of highly active antiretroviral therapy (HAART) and the onset of IRD was 11 days;
for viral infections, including those due to cytomegalovirus (14), hepatitis B virus (1), and
hepatitis C virus (2), the median interval was 42 days. As an emerging clinical entity, IRD
merits further study to optimize treatment of immunosuppressed patients.
The survival of patients with cancer, AIDS, and congenital
immunodeficiency has been improved by the development of
better anticancer and antimicrobial therapy and by the devel-
opment of effective bone marrow transplantation. Regardless
of the temporary benefit conferred by suppressing opportunistic
infections that are aggravated by the underlying illness or the
associated chemoradiotherapy, the ultimate outcome for these
patients depends on recovery of the immune system [1]. How-
ever, the clearance of preexisting asymptomatic or mildly symp-
tomatic opportunistic infections associated with immune re-
covery is not necessarily a smooth and painless process.
The local or systemic inflammatory response syndrome trig-
gered during the recovery of the innate and adaptive immune
system can result in paradoxical clinical deterioration. The de-
gree of tissue damage would depend on the tissue burden of
the preexisting microbes and the restriction or exactness of the
immune system being restored. Examples reported recently in-
clude the onset of fundoscopic deterioration with cytomega-
lovirus (CMV) retinitis and the clinical and radiological wors-
ening of pulmonary tuberculosis in patients with AIDS who
received antiretroviral therapy [2–7].
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We are not aware of any report that documents the chron-
ological changes in CD41 lymphocyte or neutrophil counts,
changes in tissue microbial load, and clinical deterioration in
HIV-negative individuals during immunorestitution. We report
the clinical, microbiological, and hematologic profiles of 2 pa-
tients with paradoxical worsening of their infections during
immune recovery and review the relevant English-language
literature.
Patients and Methods
The clinical records of the case patients were analyzed and sum-
marized. Pneumocystis carinii pneumonitis was diagnosed by me-
thenamine silver staining of 100 mL of bronchoalveolar lavage
(BAL) fluid subjected to cytospinning (Cytospin 2; Shandon, Pitts-
burgh, PA). The entire smear was examined under 4003 magni-
fication, and the number of stained cysts was quantified [8]. CMV
infection was diagnosed by semiquantitative PCR assay of plasma,
monoclonal antibody staining for the CMV pp65 antigen in pe-
ripheral blood leukocytes, and shell vial culture of a standardized
volume of BAL fluid. The longitudinal collection of plasma or
buffy-coat specimens from the case patient were retrieved from
storage at 2707C for microbiological and immunological study.
Laboratory procedures were followed as reported elsewhere [9, 10].
For semiquantitative nested PCR of CMV, 100 mL of each serum
specimen was extracted by the QIAamp DNA Mini Kit (Qiagen;
Chatsworth, CA).
The DNA extract was eluted in 100 mL of eluant provided by
the manufacturer. A serial dilution was performed (1, 1/2, 1/4, 1/10,
1/20, 1/40, and 1/100), and 10 mL of each dilution was used for
PCR. The extracts were amplified by external primers with dena-
turation at 947C for 1 min, annealing at 557C for 1 min, and
extension at 727C for 1.5 min in an automated thermal cycler (Per-
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kin-Elmer Cetus, Gouda, the Netherlands). The process was re-
peated for 20 cycles. Ten microliters of the first-round PCR am-
plicon was amplified by another set of internal primers, which
underwent a similar temperature cycle for 30 cycles. The final PCR
product of 168 bp was detected by gel electrophoresis.
A CMV pp65 antigenemia assay was performed according to
the methods of The et al. [11]. As for the shell vial culture of CMV
and detection of early antigen fluorescent foci, 200 mL of BAL fluid
was inoculated into human embryonic fibroblast cells in shell vials
incubated at 377C with 5% CO2 for 48 h. The cells were stained
with fluorescein-conjugated mouse monoclonal antibody to CMV
(Chemicon International, Temecula, CA) to detect CMV imme-
diate-early antigens and early antigens.
The CD41 lymphocyte count was determined on a peripheral
blood film using the labeled avidin biotin method (LSAB plus
alkaline phosphatase kit; Dako, Carpinteria, CA); the CD4 : CD8
ratio was also determined on a peripheral blood film but using
monoclonal antibodies to CD4 and CD8 (Dako). In brief, after
fixation of the blood film with formalin/acetone/methanol, the pri-
mary and secondary antibodies were stained with Meyer’s hema-
toxylin. We calculated the positive cells as a percentage of all lym-
phocytes present, and the CD41 and CD81 lymphocyte counts,
taking into account the absolute lymphocyte count.
Definition of immunorestitution disease (IRD). For the purpose
of this study, IRD is defined as an acute symptomatic or para-
doxical deterioration of a (presumably) preexisting infection that
is temporally related to recovery of the immune system and is due
to immunopathological damage associated with the reversal of im-
munosuppressive processes, such as withdrawal of corticosteroids,
recovery of the neutrophil count from chemotherapy, engraftment
after bone marrow transplantation, or highly active antiretroviral
therapy (HAART) for AIDS. The preexisting microbial infection
could be either asymptomatic or mildly symptomatic.
Time to development of IRD in HIV-negative patients. For
patients with preexisting viral infections due to hepatitis B virus
(HBV), parainfluenza virus, and respiratory syncytial virus, the
time to development of IRD is defined as the interval between the
withdrawal of immunosuppressive agents or the day of bone mar-
row engraftment and the onset of clinical symptoms or signs of
IRD. For patients with fungal infections due to Aspergillus or
Candida species, it is defined as the interval between the recovery
of the absolute neutrophil count (ANC) to 500 cells/mL and the
onset of IRD.
Definition of engraftment in bone marrow transplant recipients.
Engraftment is defined as a peripheral absolute neutrophil count
of 500/L.
Time to development of IRD in HIV-positive patients. For pa-
tients with preexisting viral infections due to CMV, HBV, or hep-
atitis C virus (HCV) or mycobacterial infections due to Mycobac-
terium tuberculosis, Mycobacterium avium complex, Mycobacterium
xenopi, or Cryptococcus species, the time to development of IRD
is defined as the interval between the initiation of HAART and the
onset of signs or symptoms of IRD.
Literature review. We searched the English-language literature
using the MEDLINE databases of the National Library of Med-
icine. To search for the cases in HIV-negative patients listed in
tables 1 and 2, we used the keywords “immunosuppressive with-
drawal,” “chemotherapy withdrawal,” “bone marrow transplan-
tation,” “hepatitis B,” “liver failure,” “neutrophil recovery,” “can-
didiasis,” and “aspergillosis.” To search for the cases in the
HIV-positive patients listed in tables 3 and 4, we used the keywords
“HIV,” “highly active antiretroviral therapy,” “immune reconsti-
tution,” “immune restitution,” “immune recovery,” “paradoxical,”
“opportunistic infection,” “CMV,” and “tuberculosis.” We in-
cluded all case reports and clinical studies in this study that fit our
definition of IRD. When appropriate, the cited bibliographies were
also retrieved for further analysis.
Case Reports
Case one. A 31-year-old woman was admitted to our in-
stitution (Queen Mary Hospital, Hong Kong) for investigation
of Cushing’s syndrome. She had a morning cortisol level of
3300 nmol/L (normal range, 150–720 nmol/L). Endocrine func-
tion tests confirmed the diagnosis of pituitary-dependent Cush-
ing’s disease. Therapy was started with metyrapone (11-b hy-
droxylase inhibitor) on day 0 to block the adrenal corticosteroid
synthesis, and transphenoidal resection of the functional pi-
tuitary tumor was planned (figure 1).
On admission her WBC count was normal, but the differ-
ential count revealed lymphopenia (300 cells/mL) and a CD41
lymphocyte count of 120 cells/mL. Liver function tests showed
the following values: alkaline phosphatase, 175 IU/L; alanine
aminotransferase (ALT), 67 IU/L; and aspartate aminotrans-
ferase, 38 IU/L. The liver enzyme levels continued subsequently
to increase (shown by ALT values in figure 1). CT of the he-
patobiliary system yielded normal findings. Serology for hep-
atitis A, B, and C infections was negative.
Four days after treatment with metyrapone, the patient de-
veloped persistent low-grade fever, with temperatures ranging
from 37.37C to 37.87C. Her ALT level increased to a maximum
of 416 IU/L on day 3 of metyrapone treatment but subsequently
decreased and spontaneously returned to normal without spe-
cific treatment on day 12. On the same day, she developed a
fever (temperature, 39.57C), which was associated with increas-
ing respiratory distress and arterial hypoxemia. Chest radiog-
raphy on that day showed bilateral hilar infiltration with diffuse
alveolar shadows in the lower zones, which were not visible on
the chest radiograph obtained 2 days earlier. The CD41 lym-
phocyte count was 1092 cells/mL on the day her condition began
to deteriorate.
She was transferred to the intensive care unit for ventilatory
support with 100% oxygen. Emergency bronchoscopy did not
reveal any endobronchial lesions. BAL specimens were sent for
microbiological and cytological examination. Fifty milliliters of
saline was injected in the right middle and lingular bronchi,
and 35 mL of BAL fluid was recovered. P. carinii was detected:
∼250 cysts/mL of BAL. Cytological examination revealed
abundant lymphocytes, neutrophils, and bronchial epithelial
cells. CMV was detected by shell vial culture, with 13 fluores-
cent foci per 200 mL of BAL fluid. CMV pp65 antigen testing
was positive at 3 cells/105 neutrophils.
Table 1. Summary of published cases of immunorestitution disease due to viruses in HIV-negative patients, after withdrawal of immunosup-
pressive therapy (IS) or bone marrow transplantation.
Case,
[ref]
Sex, age
in y
of patient Virus
Underlying
condition
IS agent(s)
or BMT
Time to
onset
of IRD
IRD
manifestation(s) Remarks
1 [12] M, 40 HBV CML Prd, CYT 2 w Anorexia; nausea; jaundice; HE;
Bil, 240 mmol/L; AST, 700 IU/L
Died despite steroid treatment; liver biopsy:
massive hepatic necrosis
2 [12] F, 28 HBV Choriocarcinoma CYT 4 w Anorexia; jaundice; HE; Bil, 410
mmol/L; AST, 600 IU/L
Died; liver biopsy: massive hepatic necrosis
3 [12] M, 32 HBV CLL Prd, CYT 6 w Malaise; anorexia; jaundice; Bil,
550 mmol/L; AST, 1270 IU/L
Died; liver biopsy: massive hepatic necrosis
4 [13] F, 35 HBV Renal transplant Aza (100 mg/d),
Prd (10 mg/d)
2 w Jaundice; abnormal liver func-
tion test findings
Withdrawal of IS due to peritonitis; died;
1st liver biopsy: centrilobular necrosis;
2d liver biopsy: massive hepatic necrosis
5 [14] M, 49 HBV Malignant lymphoma Prd, CYT 3 w Progressive anorexia; fever; ar-
thralgia; myalgia; increasing
ascites; Bil, 11.9 mg/dL; ALT,
4495 IU/L
Died despite steroid treatment; liver biopsy:
massive hepatic necrosis
6 [15] M, 15 HBV Nephrotic syndrome Prd (50 mg/d),
tapered over 2 w
16 d Malaise; anorexia; nausea; jaun-
dice; tender hepatomegaly; Bil,
85 mmol/L; ALT, 1350 IU/L
Died; liver biopsy: massive hepatic necrosis
7 [15] M, 60 HBV Nephrotic syndrome CTX (150 mg/d) 2 w Lassitude; anorexia; ascites; jaun-
dice; Bil, 92 mmol/L; ALT,
1800 IU/L
Died; liver biopsy: massive hepatic necrosis
8 [16] M, 43 HBV Behcet’s disease CTX (160 mg/d),
MP (250 mg/mo)
2 w Grade I HE; jaundice; Bil, 46
mmol/L; ALT, 520 IU/L
Died despite steroid treatment; liver biopsy:
cirrhotic liver with advanced necrosis
9 [16] M, 39 HBV Follicular lymphoma Prd, CYT 3 w Jaundice; HS; Bil, 315 mmol/L;
ALT, 2180 IU/L
Died despite steroid treatment; liver biopsy:
extensive area of confluent necrosis
10 [16] M, 40 HBV Renal transplant Prd (25 mg/d),
CysA (200 mg/d),
Aza (100 mg/d)
2 w Confusion; Bil, 67 mmol/L; AST,
2103 IU/L
Withdrawal of IS due to uncontrolled hy-
pertension; died despite steroid treat-
ment; no liver biopsy
11 [16] F, 55 HBV Hodgkin’s disease Prd, CYT 2 w Jaundice; upper abdominal pain;
ascites; Bil, 258 mmol/L; AST,
1782 IU/L
Died despite steroid treatment; liver biopsy:
cirrhosis, mixed inflammatory infiltrate
in portal tract
12 [16] F, 52 HBV Ca cervix CYT 6 w Jaundice; HE; Bil, 135 mmol/L;
ALT, 3585 IU/L
Died; liver biopsy: massive hepatic necrosis
13 [17] F, 59 HBV Hodgkin’s disease Prd, CYT 3 w Symptoms of hepatitis; ALT
peak, 2600 IU/L
Died; liver biopsy: massive hepatic necrosis
14 [17] F, 32 HBV Hodgkin’s disease Prd, CYT 4 w NM Died; liver biopsy: massive hepatic necrosis
15 [17] M, 36 HBV Hodgkin’s disease Prd, CYT 4 w NM Died; liver biopsy: massive hepatic necrosis
16 [17] M, 52 HBV Hodgkin’s disease Prd, CYT 3 w NM Died of liver failure
17 [18] F, 57 HBV Rheumatoid arthritis Mtx (7.5–10 mg/w
orally)
41 d Fulminant hepatic failure Survived; liver transplantation on d 53
18 [19] M, 63 HBV Malignant lymphoma Prd, CYT 28 d Jaundice; abdominal pain; ascites;
Bil, 25.5 mg/dL; ALT, 540 IU/L
Died despite steroid treatment; liver biopsy:
bridging necrosis and portal fibrosis
19 [19] F, 60 HBV CLL Prd, CYT 38 d Fever; jaundice; HS; ascites; Bil,
18.8 mg/dL; ALT, 760 IU/L
Died of hepatic failure; no postmortem
20 [19] M, 34 HBV Malignant lymphoma Prd, CYT 10 d Anorexia; fatigue; jaundice; ab-
dominal pain; Bil, 4.9 mg/dL;
ALT, 1100 IU/L
Died despite steroid treatment; liver biopsy:
submassive hepatic necrosis and mild
portal fibrosis
21 [19] M, 56 HBV Malignant lymphoma Prd, CYT 2 w Nausea; Bil, 9.9 mg/dL; ALT,
1710 IU/L
Survived with steroid treatment; liver bi-
opsy: severe degree of multifocal necrosis
22 [19] F, 28 HBV Malignant lymphoma Prd, CYT 17 d Fatigue; nausea; jaundice;
Bil, 9.1 mg/dL; ALT, 397 IU/L
Died of hepatic failure; no postmortem
23 [20] NM PIF1 SCID BMT NM Postengraftment pneumonitis Died of pneumonitis
24 [20] NM PIF2 SCID BMT NM Postengraftment pneumonitis Survived after treatment with inhaled
budesonide
25 [20] NM PIF3 SCID BMT NM Postengraftment pneumonitis Died of pneumonitis
26 [20] NM PIF3 SCID BMT NM Postengraftment pneumonitis Died of pneumonitis
27 [20] NM PIF4 SCID BMT NM Postengraftment pneumonitis Died of pneumonitis despite inhaled
budesonide
28 [20] NM RSV SCID BMT NM Postengraftment pneumonitis Died of pneumonitis
29 [21] M, 27 HBV CML BMT 59 d Ascites; HE; increasing ALT Engrafted on d 17; liver biopsy on d 44
showed active lobular hepatitis with ne-
crosis; died d 130; no postmortem
30 [22] F, 19 HBV CML BMT 74 d Jaundice; hepatomegaly; worsen-
ing of liver function test
findings
Engrafted on d 18; died despite steroid treat-
ment; liver biopsy: submassive necrosis
and large area of balloon degeneration
NOTE. ALT, alanine aminotransferase level; AST, aspartate aminotransferase level; Aza, azathioprine; Bil, bilirubin level; BMT, allogeneic bone marrow trans-
plantation; Ca, carcinoma; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CTX, cyclophosphamide; CysA, cyclosporin A; CYT, cytotoxic
agents; HBV, hepatitis B virus; HE, hepatic encephalopathy; HS, hepatosplenomegaly; IRD, immunorestitution disease; MP, methylprednisolone; Mtx, methotrexate;
NM, not mentioned; ref, reference; PIF1, parainfluenza virus serotype 1; PIF2, parainfluenza virus serotype 2; PIF3, parainfluenza virus serotype 3; PIF4, parainfluenza
virus serotype 4; Prd, prednisone; ref, reference; RSV, respiratory syncytial virus; SCID, severe combined immunodeficiency disease.
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Table 2. Summary of published cases of immunorestitution disease in HIV-negative patients with aspergillosis and hepatosplenic candidiasis
after recovery of the absolute neutrophil count (ANC).
Case(s) [ref]
Sex (n),
age in y
of patient(s)
Preexisting
infection Disease
ANC, cells/mL
Time to
onset
of IRD, d IRD manifestation(s) Remarks
Before
IRD
During
IRD
31–38 [23] NM Asp Hemic mala !500 1500 NM Pulmonary cavitation, followed
by hemoptysis
1 patient died of massive hemoptysis
39–45 [24] M (4) F (3),
median, 42
[rng, 36–69]
Asp AML, 5;
ALL, 2
!500 Mean, 7200 Mean, 7 Cough, pain, bronchospasm
worsening of CXR lesion;
massive hemoptysis
6 patients died; diagnosis confirmed
by autopsy; 1 case diagnosed by
serology and sputum smear
46–53 [25] NM Asp Hemic malb !500 Mean, 6577 Mean, 5–11 Massive hemoptysis in 4 pa-
tients; 3 had pneumothorax,
1 had both
5 patients died of pulmonary
complications
54 [26] M, 20 HSC RMS !50 25,000 10 Recurrent fever, RUQ abdomi-
nal pain
Died; autopsy showed numerous
granulomas in liver, spleen,
kidney
55 [26] M, 12 HSC ALL !500 15,400 5 Recurrent fever, severe nausea,
vomiting; CT showed lesion
in liver, spleen, kidney, pul-
monary nodules
Liver biopsy finding consistent with
candidal infection; autopsy
showed single granulomatous area
with necrosis and residual hyphae
in spleen
56 [26] F, 22 HSC ALL !500 1500 2 Abdominal pain Laparotomy and histology showed
multiple hepatic abscesses with
budding yeast and pseudohyphae;
culture confirmed C. albicans; sur-
vived after receipt of AmB (total,
7.5 g); repeated liver biopsy
showed no residual disease
57–61 [27] M (1) F (4),
median, 41
[rng, 18–47]
HSC ALL, 2;
AML, 3
!500 1500 Median, 20
[rng, 7–46]
Reappearance or increase in
hepatosplenic lesions on CT
CT used to follow evolution of le-
sions during
and after neutropenia
NOTE. ALL, acute lymphoblastic leukemia; AmB, amphotericin B; AML, acute myeloid leukemia; Asp, aspergillosis; CXR, chest radiographic; Hemic mal,
hemic malignancy; HSC, hepatosplenic candidiasis; IRD, immunorestitution disease; ref, reference; RMS, rhabdomyosarcoma of left maxillary sinus; rng, range; RUQ,
right upper quadrant;
a Acute leukemia.
b Including acute leukemia or high-grade lymphoma.
After metyrapone treatment, the morning cortisol level pro-
gressively decreased from 2270 nmol/L (day 0) to 575 nmol/L
(day 12) (figure 1). The drop in cortisol level was associated
with normalization of the absolute lymphocyte count, from 300
cells/mL to 2600 cells/mL, whereas the CD41 lymphocyte count
increased to 1092 cells/mL. Concurrent semiquantitative PCR
of stored plasma taken on day 0 and day 12 showed a 10-fold
decrease in CMV DNA titer after treatment with metyrapone.
The tentative diagnosis was that during recovery of the CD41
lymphocyte count, asymptomatic clearance of CMV hepatitis
had occurred but pneumonitis developed as a result of a severe
inflammatory response to P. carinii and possibly CMV. The
patient was treated for P. carinii pneumonitis with high-dose
trimethoprim (20 mg/kg/d) and sulfamethoxazole (100 mg/kg/d)
in 4 divided doses for 21 days. Tapering doses of adjuvant
corticosteroid were given as recommended [34]. For treatment
and prevention of possible concomitant CMV pneumonitis and
systemic CMV disease, ganciclovir (250 mg iv every 12 h) was
given along with tapering doses of methylprednisolone. The
patient recovered completely and was discharged on day 30.
Her serum was negative for HIV antibody.
Case two. A 51-year-old woman at our hospital who had
acute myeloid leukemia was noted to have fever and an asymp-
tomatic radiographic pulmonary consolidation over the left-
mid–zone before induction chemotherapy. Blood and sputum
culture for bacteria, fungi, and acid-fast bacilli were negative,
and induction chemotherapy with cytosine arabinoside (100
mg/m2) and daunorubicin (50 mg/m2) was started under cov-
erage with iv ceftazidime (2 g every 8 h). Because of the per-
sistence of fever, neutropenia (ANC, 30/mL), and radiographic
pulmonary changes, bronchoscopy and BAL were performed
on day 7 of chemotherapy. Culture of the BAL fluid yielded
Aspergillus terreus, but the concentrated smear was negative
[35].
The patient was given ceftazidime and amphotericin B (1 mg/
kg/d) for prolonged neutropenic fever and pulmonary asper-
gillosis. The WBC count started to recover on day 36, at which
time ANC was 530 cells/mL. Ten days later the ANC had in-
creased to 1500 cells/mL, but there was a progressive increase
in blood-streaked sputum, pleuritic chest pain, and fever. Re-
peated chest radiography showed an enlarging left-mid–zone
shadow with evidence of cavitation and abscess formation.
Bronchoscopy was performed on day 54 and revealed mucosal
swelling at the apical segment of the left lower lobe. Exami-
nation of a direct smear of the BAL fluid showed the presence
of fungal elements and numerous neutrophils. The concomitant
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Table 3. Summary of published cases of immunorestitution disease (IRD) in HIV-positive patients due to viruses after highly active antiretroviral
therapy (HAART).
Case [ref]
Sex, age
in y
of patient Virus
CD4 cells/mL HIV RNA, copies/mL
Time to
onset
of IRD IRD manifestation (treatment)
Before
HAART
After HAART,
during IRD
Before
HAART
After
HAART
62 [2] M, 34 CMV 82 266 NM NM 7 w Retinitis
63 [2] M, 43 CMV 70 213 NM NM 5 w Retinitis, vitritis
64 [2] M, 35 CMV 14 205 NM NM 4 w Retinitis, vitritis
65 [2] M, 47 CMV 18 197 NM NM 5 w Retinitis
66 [2] M, 45 CMV 40 270 NM NM 6 w Retinitis
67 [3] M, 33 CMV 4 70 80,000 6000 NM Retinitis
68 [3] M, 39 CMV 33 144 374,000 83,584 NM Retinitis
69 [3] M, 30 CMV 5 190 341,000 !400 NM Retinitis
70 [3] M, 54 CMV 88 200 600,000 42,210 6 w Retinitis
71 [4] M, 43 CMV 17 300 NM UD 5 mo Decreased visual acuity and floaters; vitritis and papillitis
72 [4] M, 32 CMV 47 234 NM UD 2 mo Decreased visual acuity and floaters; vitritis and papilli-
tis; cystoid macular edema
73 [4] M, 44 CMV 22 63 NM UD 2 mo Decreased visual acuity and floaters; vitritis and papilli-
tis; macular edema (oral steroid)
74 [4] NM CMV 18 104 NM UD 2 mo Decreased visual acuity and floaters; vitritis and papilli-
tis; cystoid macular edema (repository steroid
injection)
75 [4] NM CMV 28 79 NM UD 3 mo Decreased visual acuity and floaters; vitritis and papillitis
76 [28] M, 34 HBV 130 NM NM 100-fold reduced 6 w Vomiting, tender hepatomegaly with increased ALT; liver
biopsy at week 10 showed acute lobular hepatitis; by
week 24, 10,000-fold reduction of HBV DNA and
clearance of HBeAg
77 [29] M, 36 HCV 32 138 545,000 !260 4 w Anorexia, jaundice, tender hepatomegaly; serum ALT,
301 IU/L (peaked at 24 w); liver biopsy showed
chronic hepatitis
81 [29] M, 30 HCV 14 154 579,000 !260 2 mo Vomiting, tender hepatomegaly; pruritic blistering erup-
tion of cutaneous porphyria noted on hands; ALT,
460 IU/L
NOTE. ALT, alanine aminotransferase level; CMV, cytomegalovirus; HAART, highly active antiretroviral therapy; HBeAg, hepatitis B e antigen; HBV, hepatitis
B virus; HCV, hepatitis C virus; NM, not mentioned; ref, reference; UD, undetectable.
peripheral blood ANC was 2400 cells/mL. A. terreus was again
cultured from the BAL fluid. She recovered after 102 days of
therapy with iv amphotericin B (total dose, 4 g), and consol-
idation chemotherapy was continued.
Literature Review
Our review of the literature in English found a total of 109
disease episodes (cases) in 107 patients that fit the definition of
IRD. The patients’ ages ranged from 12 to 69 years, with a
median of 38 years. Forty cases were in males and 23 in females;
for 46 cases, the age and sex of the patient were not mentioned.
Sixty-one patients (tables 1 and 2) were HIV-negative patients
with hematologic malignancies (46), solid tumors (3), nephrotic
syndrome (2), autoimmune diseases (2), severe combined im-
munodeficiency (6), or renal transplants (2). Among these HIV-
negative patients, the source of immunosuppression was steroid
therapy alone (1.6%), cytotoxic therapy alone (55.8%), steroid
and cytotoxic therapy (29.5%), or bone marrow transplantation
(13.1%). Preexisting infections were those due to Aspergillus
species (37.7%), Candida species (13.1%), HBV (39.3%), par-
ainfluenza virus (8.2%), and respiratory syncytial virus (1.7%).
The median time from recovery of neutrophil counts or the
end of steroid therapy to the development of IRD was 8 days
for pulmonary aspergillosis and hepatosplenic candidiasis and
21 days for viral diseases, such as hepatitis B and viral pneu-
monitis. In 14 cases, this time interval was not mentioned. The
outcome was not mentioned in 6 cases, but 41 of (67.2%) 61
patients died. Eleven patients were treated with inhaled or sys-
temic steroids for IRD, but only 2 of them survived.
Clinical features of pulmonary aspergillosis included hemop-
tysis, cough, pleuritic chest pain, pneumothorax, and radio-
graphic worsening in terms of enlargement of lesions, cavita-
tion, or effusion. Manifestations of hepatosplenic candidiasis
included abdominal pain, increasing ductal enzyme levels, and
ultrasonographic evidence of enlarging abscess with the typical
bull’s eye lesion. Viral pneumonitis was predominantly mani-
fested by respiratory failure and diffuse interstitial radiographic
changes typical of pneumonitis. Deterioration due to hepatitis
B presented as jaundice, upper abdominal pain, ascites, and
features of hepatic failure.
Forty-six HIV-positive patients (tables 3 and 4) who had 48
episodes of IRD were reviewed. All episodes were related to
the institution of HAART. Before the initiation of therapy, the
CD41 lymphocyte count ranged from 2 cells/mL to 220 cells/
mL, with a median of 26 cells/mL. After HAART, the CD41
lymphocyte count increased to a median of 149 cells/mL and
ranged from 5 cells/mL to 420 cells/mL. In 4 reported episodes
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Figure 1. Profile of cortisol levels (m), lymphocyte counts (m), and liver function values (l) before and after metyrapone therapy for patient
1. A, CD41 lymphocyte count, cells/mL. B, CD41 lymphocyte count, cells/mL. C, Commencement of 21 days of methyl-9 9120 3 10 1092 3 10
prednisolone treatment. ALT, alanine aminotransferase level.
(cases 83a, 84, 89, and 90), there was a decrease in CD41 lym-
phocyte counts after initiation of HAART. The organisms that
caused IRD included M. tuberculosis (35.4%), M. avium com-
plex (18.7%), M. xenopi (2.1%), Cryptococcus species (8.4%),
CMV (29.1%), HBV (2.1%), and HCV (4.2%).
For mycobacterial and fungal infections, the median interval
between initiation of HAART and the onset of IRD was 11
days, whereas the interval for viral infections was 42 days. The
interval was not mentioned for 4 cases. Fever was reported to
occur in 20 (74%) of 27 cases of mycobacterial disease and in
3 of 4 cases of cryptococcal infection but not in those of viral
disease. Ocular manifestations of CMV disease included visual
loss and fundoscopic changes of inflammatory retinitis, vitritis,
papillitis, and macular edema. Abdominal pain, ascites, pleural
effusion, hepatosplenomegaly, testicular enlargement, tender
cervical lymphadenopathy, and skin lesions were reported to
occur in the cases of mycobacterial disease.
Chest radiography and CT scanning revealed effusions, me-
diastinal and retroperitoneal lymph node enlargement, and
worsening pulmonary parenchymal or miliary shadows. Focal
necrotizing lymphadenitis with well-formed granulomas was
noted in patients with M. avium complex infection. The man-
ifestations of HBV and HCV infection were similar to those in
HIV-negative patients. No deaths caused by IRD were reported
to occur among HIV-positive patients. Good response was ob-
tained with the use of systemic steroids (8 cases), repository
steroids (1), and a nonsteroidal anti-inflammatory agent (1).
Discussion
The immune system has been demonstrated to play a critical
role in host defense against opportunistic infections in neutro-
penic patients recovering from chemoradiotherapy, patients
with AIDS who are receiving HAART, and congenitally im-
munodeficient patients who are undergoing immunoglobulin
replacement or have undergone bone marrow transplantation.
However, there are also anecdotal reports on the deleterious
and occasionally fatal effects of inflammatory or immuno-
pathological damage that comes with restitution of the immune
system [12–18].
Many terms have been used to describe this disease entity,
including immune recovery disease [4], immune reconstitution
disease [36], immune restoration disease [29, 37], immune re-
bound illness [38, 39], and steroid-withdrawal disease [19]. The
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term “immunorestitution disease” is used here to express the
concept of immunosuppression followed by a “bouncing back”
of the immune system. Attention to this disease entity was
recently raised by a series of reports concerning HIV-positive
patients presenting with a paradoxical inflammatory response
to preexisting viral and mycobacterial infections after HAART
[2–7]. However, little attention has been devoted to the existence
of a similar entity in HIV-negative patients, and a clear and
encompassing concept of IRD related to innate and adaptive
immunity has not yet been formulated.
IRD related to adaptive immunity is illustrated in our first
case. The onset of severe P. carinii pneumonitis and possibly
CMV pneumonitis occurred while the CD41 lymphocyte count
was 1092 cells/mL, on day 12 of metyrapone therapy for Cush-
ing’s disease. Though low-grade fever started on day 4 of me-
tyrapone therapy, there were no clinical and radiographic fea-
tures suggestive of inflammatory damage of the lungs until
recovery of the CD41 lymphocyte count. It is interesting that
the liver function improved as the CD41 lymphocyte count
increased, a circumstance suggesting that the patient might have
had CMV hepatitis during immunosuppression with high levels
of endogenous steroid.
Systemic CMV infection was also evidenced by a 10-fold
reduction in CMV DNA in the blood after recovery of the
CD41 lymphocyte count. It is presumed that both CMV and
P. carinii were present in the lungs subclinically before the CD41
lymphocyte count increased. However, we concede that there
is an extremely low possibility that the P. carinii pneumonia
was incidentally acquired when the CD41 lymphocyte count
was normal and at the highest point in the course of the pa-
tient’s illness. The CD41 lymphocyte count decreased rapidly
to 600 cells/mL on the day of clinical deterioration before ini-
tiation of therapy with methylprednisolone, presumably be-
cause of CD41 lymphocyte migration into the lungs, as evi-
denced by the numerous lymphocytes detected in the BAL
specimen. This may also explain the decrease in CD41 lym-
phocyte count during IRD in the 4 patients receiving HAART
(cases 83a, 84, 89, and 90; 4).
IRD related to innate immunity is illustrated by the second
case. Similar cases have been reported in the literature but not
from the perspective of paradoxical inflammatory damage due
to recovery of the innate immune system [23, 24]. Unlike pre-
viously reported cases, our patient had preexisting A. terreus
infection; presence of the organism in BAL during neutropenia
was documented. Clinical symptoms and radiographic changes
worsened while the neutrophil count increased to 2400 cells/
mL. The release of proteolytic enzymes from neutrophils, caus-
ing lung-tissue destruction, probably facilitated the release of
the hyphae into the bronchial lumen and pulmonary vascula-
ture [23]. This may explain why only the second BAL specimen
revealed typical findings of septated branching hyphae with
dichotomous branching and numerous neutrophils, as well as
the subsequent hemoptysis and radiological deterioration.
Preexisting asymptomatic or mildly symptomatic infections
were documented clinically, serologically, or microbiologically
in 86 (78.9%) of 109 episodes of IRD reported in the literature.
In some cases, the preexistence of the microbes was presumed
because the pathogen was much more likely to have been ac-
quired during the intense immunosuppression than when the
relevant laboratory markers of the immune system were already
within normal limits. As expected, the infecting organisms in
IRD were either slow growers, such as M. tuberculosis and
Cryptococcus species, or opportunistic pathogens of relatively
low virulence, such as M. avium complex, Aspergillus, and Can-
dida. Similarly, the damage caused by latent viruses such as
HBV is mainly immunopathological and may appear only after
immunorestitution.
No pyogenic bacterial infection in cases of IRD was reported,
probably because of the almost universal usage of potent and
effective antimicrobials or because the fulminant course of se-
vere pyogenic infections during immunosuppression would
have resulted in early death.
Immune recovery was well documented in most of the HIV-
positive patients by an increase in CD41 lymphocyte counts,
even though the interval between the onset of symptoms and
the determination of CD41 lymphocyte counts was not men-
tioned in many reports. In some HIV-negative cases, immune
recovery after the administration of steroids or cytotoxic agents
ended was only inferred since the exact dates of cell count
determinations were not mentioned. The number of circulating
neutrophils or CD41 lymphocytes does not always reflect their
number in the involved tissues or their in vivo functional status.
Even less is known about the relationship of IRD to pathogen-
specific CD41 and CD81 lymphocytes and antibody subsets.
Thus, in cases 83a, 84, 89, and 90, the CD41 lymphocyte count
apparently decreased despite HAART and does not necessarily
exclude IRD.
Though a clear temporal sequence was apparent, the interval
between the onset of immune recovery and IRD was variable.
It appeared that in both HIV-positive and HIV-negative pa-
tients, the period was 21–42 days for viruses and only 8–11
days for fungal and mycobacterial diseases. The latter patho-
gens are nonobligatory intracellular or extracellular organisms,
in contrast to viruses, which are obligatory intracellular path-
ogens. This phenomenon raised the possibility that the path-
ogen-specific adaptive CD81 cytotoxic T cell response may re-
cover later than does innate neutrophil-mediated or adaptive
CD41 cell–mediated immunity. This postulation was con-
founded by the difference in the definition of this interval and
the fact that the CD81 lymphocyte count may not correlate
with the degree of virus-specific lymphocytic cytotoxicity.
Clinical manifestations of opportunistic infections during im-
munosuppression are characterized by a high microbial tissue
burden and systemic dissemination. In contrast, the manifes-
tations of IRD are characterized by severe inflammatory and
typical host responses to preexisting microbes. In patients with
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prolonged neutropenia and disseminated fungal infections due
to Aspergillus and Candida species, fever was the only initial
symptom, and subsequent dissemination to skin, brain, and
viscera often occurred concomitantly with shock. In patients
with pulmonary aspergillosis, radiographic lesions during im-
munosuppression that were shown by chest radiography or CT
scanning were due to the presence of mold or infarcted tissue.
During immunorestitution, pulmonary cavitation with cen-
tral necrosis and massive hemoptysis might become clinically
and radiologically overt [23, 24]. As for hepatosplenic candi-
diasis during immunorestitution, severe nausea, vomiting, up-
per abdominal pain, elevated alkaline phosphatase levels, ul-
trasonographic evidence of multiple well-formed abscesses with
bull’s eye lesions, and histologic findings of granulomatous in-
flammation with microabscesses and hyphae or pseudohyphae
have been reported [40–44].
Primary or reactivated M. tuberculosis infection in immu-
nosuppressed hosts may be rapidly progressive and be mani-
fested by persistent fever, wasting, and extrapulmonary spread
with high mycobacterial load [45, 46]. Chest radiography may
yield normal findings or show miliary lesions. Skin tests with
purified protein derivative (PPD) were always negative in our
study. During immunorestitution, a severe inflammatory re-
sponse to both pulmonary and extrapulmonary foci loaded
with acid-fast bacilli resulted in worsening of pulmonary le-
sions, hypertrophy, and hyperplasia of the reticuloendothelial
tissues of the liver, spleen, and lymph nodes. Histologic evidence
of granulomatous inflammation would appear and the PPD
skin test would turn positive [5–7].
In patients with AIDS whose CD41 lymphocyte counts were
!200 cells/mL, CMV retinitis was characterized by noninflam-
matory necrotizing lesions even in the presence of extensive
retinal involvement, distinct from the fundoscopic changes of
inflammatory retinitis, vitritis, papillitis, and macular edema
that occurred after treatment with HAART [2–4]. In patients
with severe combined immunodeficiency, respiratory viral in-
fections due to parainfluenza virus and respiratory syncytial
virus could present with mild upper or lower respiratory symp-
toms, with high levels of viral shedding. At the time of en-
graftment after bone marrow transplantation, there could be
rapid deterioration, with fulminant pneumonitis and respira-
tory failure [20].
Diagnosis of IRD is never simple or straightforward since
there are no clinical or laboratory tests that are specific for
IRD. Indeed, IRD is a diagnosis of exclusion. During immu-
norestitution, paradoxical worsening of clinical symptoms and
signs of a preexisting infection should be carefully investigated.
Such presentations may be a result of inadequate antimicrobi-
al therapy, development of drug resistance, superinfection by
other organisms, or development of noninfectious complica-
tions. A diagnosis of IRD can be made after all these possi-
bilities are excluded.
Development of IRD probably requires an interaction be-
tween the tissue burden of preexisting microbes, virulence of
the organism, and exactness or restriction of the immune sys-
tem. Three combinations can be envisaged. First, patients with
a high microbial load or infected with more virulent microbes
may die of overwhelming sepsis even before recovery of the
immune system. This is exemplified by the absence of pyogenic
bacterial infections reported in IRD. Second, patients with a
low microbial burden and orderly recovery of the immune sys-
tem may have only subclinical IRD, so the diagnosis may be
missed. Thus only the third group of patients, those with an
appropriately significant microbial burden and relative “over-
shooting” of immune recovery, may have a clinically significant
systemic or local inflammatory response during immunoresti-
tution. Factors affecting the onset and severity of IRD during
immune recovery still await further study.
Morbidity was clearly documented for IRD, as systemic or
local inflammatory response and loss of function. However,
mortality attributed to IRD was not as certain. No mortality
was reported for AIDS patients receiving HAART, but a high
mortality was noted among HIV-negative patients. This phe-
nomenon is primarily confounded by the lack of highly effective
antifungal or antiviral therapy against Aspergillus, Candida,
and hepatitis and respiratory viruses.
The therapeutic intervention for IRD is not well established.
The use of appropriate antimicrobial agents is the prerequisite
for success in most cases. Anti-inflammatory agents such as
nonsteroidal drugs and local or systemic steroids seem to give
promising results in terms of arrest of the acute inflammatory
damage during IRD after initiation of HAART in HIV-positive
patients. However, the results of steroid use for hepatitis flare-
ups induced by chemotherapy withdrawal were disappointing
in patients with chronic hepatitis B.
The ideal situation in the treatment of IRD is to attain exact
control of the overwhelming immune system by immunomo-
dulation. For example, iv infusion of immunoglobulin com-
bined with ganciclovir has been proven to reduce the mortality
associated with postengraftment CMV pneumonitis in bone
marrow transplant recipients [47]. It should also be investigated
for use against IRD related to respiratory syncytial virus and
parainfluenza virus infection. Recently, a combination of tha-
lidomide plus antibiotics was shown to protect rabbits in an
experimental model from death due to tuberculous meningitis,
via the inhibition of tumor necrosis factor [48]. Although the
role of interleukins and cytokines in IRD is still uncertain,
immunotherapy should be the future direction of treatment.
IRD may be prevented if asymptomatic infection is screened
for and appropriate prophylaxis is given before and throughout
the period of immunosuppression. However, it seems imprudent
to treat all such asymptomatic patients, since it appears that
only a minority will develop immunopathological damage. Pro-
phylaxis should be considered for certain high-risk patients such
as bone marrow transplant recipients. Antimicrobial therapy
plus short-term immunosuppression with gradual dose reduc-
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tion may decrease morbidity and prevent permanent functional
loss [5, 6].
Preemptive immunosuppression with steroids, without si-
multaneous effective antimicrobial coverage, is probably coun-
terproductive in the treatment of IRD. Adoptive transfer of
pathogen-specific immune function may also be effective in pre-
venting the onset of symptomatic disease when the tissue bur-
den of the pathogen is still low. This was illustrated by the
prophylactic use of CMV-specific cytotoxic T lymphocytes in
allogeneic bone marrow transplant recipients [49]. This thera-
peutic modality is especially important if no effective antimi-
crobial is available or resistance to prophylaxis develops rapidly.
IRD is an emerging clinical entity that merits further study.
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